Preparation method of amorphous zirconia with chemical power treatment effect
Amorphous zirconia nanomaterials prepared by hydrothermal reaction have solved the problems of insufficient catalytic activity and low biosafety of existing nanocatalysts, achieving highly efficient chemodynamic therapy with good biocompatibility and low toxicity.
Patent Information
- Application Number
- CN202510922546.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-07-04
- Publication Date
- 2025-11-07
AI Technical Summary
Existing iron-based, copper-based, cobalt-based, and manganese-based nanocatalysts suffer from insufficient catalytic activity, low biosafety, and poor stability in chemodynamic therapy, limiting their application in tumor treatment.
Amorphous zirconium oxide (a-ZrO2) was used as a novel nanomaterial. Through a hydrothermal reaction process, oxygen vacancies were introduced to improve its ROS generation efficiency in the tumor microenvironment, thus preparing a novel tumor therapeutic drug with chemodynamic therapeutic effects.
The prepared amorphous zirconia material exhibits high biocompatibility, low biotoxicity, and excellent therapeutic effects. It can effectively regulate redox reactions in the tumor microenvironment and improve therapeutic efficacy.
Smart Images
Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
TECHNICAL FIELD
[0001] The present application relates to the field of chemical drugs, in particular to a preparation method and application of amorphous zirconium oxide with chemodynamic therapy effect. BACKGROUND
[0002] With the rapid development of nanobiomedicine, tumor treatment triggered by exogenous stimuli has become a research hotspot. Chemodynamic therapy (CDT) has attracted widespread attention due to its advantages of not requiring external energy input and relying on the characteristics of tumor microenvironment (TME) to trigger the generation of reactive oxygen species (ROS). The core mechanism of CDT is to use transition metals to catalyze endogenous molecules such as hydrogen peroxide (H2O2) or glutathione (GSH) in tumor tissues to generate hydroxyl radicals (·OH) through Fenton or Fenton-like reactions, thereby inducing tumor cell oxidative stress damage and apoptosis. However, the currently widely studied CDT nanomaterials, such as iron-based, copper-based, cobalt-based and manganese-based nanocatalysts, still have problems such as insufficient catalytic activity, low biological safety and poor stability, which limit their clinical application.
[0003] Amorphous zirconium oxide (a-ZrO2) is a new inorganic nanomaterial that has broad application prospects in catalysis, biomedicine and functional materials due to its unique structural defects and excellent chemical stability. Compared with crystalline zirconium dioxide, amorphous zirconium oxide has higher specific surface area and abundant surface active sites, which enables it to effectively regulate the redox reaction in the tumor microenvironment. In addition, the low biological toxicity and good biocompatibility of zirconium oxide make it a potential high-efficiency CDT nanocatalyst. Studies have shown that the introduction of oxygen vacancies can further enhance the catalytic activity of amorphous zirconium oxide and promote its ROS generation efficiency in the tumor microenvironment, thereby improving the therapeutic effect of CDT. Therefore, it is of great significance to synthesize amorphous zirconium dioxide (a-ZrO2) and study its application in tumor diagnosis and treatment. SUMMARY
[0004] In view of the problems of single action and poor effect of current tumor treatment drugs, the present application aims to synthesize a new tumor treatment drug with chemodynamic therapy effect, high biocompatibility and low biological toxicity.
[0005] The technical solution of the present application is as follows: The preparation method of amorphous zirconium oxide with chemodynamic therapy effect, characterized by comprising the following steps: (1) Dissolve zirconium oxychloride octahydrate in deionized water and stir for 5 min. Add a certain volume ratio of ammonia water and stir for 5 min.
[0006] (2) The solution of the above step is transferred to a high-pressure reaction kettle for hydrothermal reaction, and is reacted at 150 DEG C for 3 h. After the reaction, when the temperature of the reaction kettle is reduced to room temperature, the obtained material is centrifuged, washed with deionized water for three times, and finally placed at 60 DEG C for drying for 12 h to obtain the final material.
[0007] Further, the concentration of the zirconium octahydrate oxychloride in the step (1) is 0.1-0.5 mg / mL.
[0008] Further, the concentration of the ammonia water in the step (1) is 20%-30%.
[0009] Further, the volume ratio of the zirconium octahydrate oxychloride to the ammonia water in the step (1) is 2:1.
[0010] The present application has the following advantages: In view of the problems of single action and poor effect of the current tumor treatment drugs, the present application creatively prepares a novel tumor treatment drug with simple preparation process, good biocompatibility, low biological toxicity, strong stability and excellent treatment effect. BRIEF DESCRIPTION OF DRAWINGS
[0011] In order to make the purpose, technical scheme and beneficial effects of the present application clearer, the present application provides the following drawings:
[0012] Figure 1 The XRD graph of the amorphous zirconium oxide with chemical dynamic treatment effect in Example 1 of the present application.
[0013] Figure 2 The in vitro toxicity graph of the amorphous zirconium oxide with chemical dynamic treatment effect in Example 1 of the present application on L929 cells for 24 h.
[0014] Figure 3 The in vitro toxicity graph of the amorphous zirconium oxide with chemical dynamic treatment effect in Example 1 of the present application on K7M2 cancer cells for 24 h.
[0015] Figure 4 The in vivo anti-tumor effect graph of the amorphous zirconium oxide with chemical dynamic treatment effect in Example 1 of the present application. DETAILED DESCRIPTION
[0016] The following examples are used to illustrate the present application, but not to limit the scope of the present application.
[0017] Example 1
[0018] (1) 2 g of zirconium octahydrate oxychloride is dissolved in 20 mL of deionized water, and stirred for 5 min. 10 mL of ammonia water with a concentration of 28% is added, and stirred for 5 min.
[0019] (2) The solution of the above step is transferred to a high-pressure reaction kettle for hydrothermal reaction, and reacted at 150°C for 3h. After the reaction, when the temperature of the reaction kettle drops to room temperature, the obtained material is centrifuged, washed with deionized water for three times, and finally placed in a 60°C drying oven for 12h to obtain the final material.
[0020] The X-ray diffraction (XRD) of the nanoparticles is shown in Figure 1 The XRD result shows that the nanoparticles are amorphous materials. Figure 2 The biocompatibility graph of the nanoparticles with L929 cells cultured for 24h without external stimulation can be seen that the normal cells have good biological safety to the normal cells. Figure 3 The in vitro toxicity graph of the nanoparticles on K7M2 tumor cells for 24h without external stimulation can be seen from the graph that the toxicity of the nanoparticles on K7M2 tumor cells shows a concentration-dependent killing effect.
[0021] Finally, it should be pointed out that the above preferred embodiments are only used to illustrate the technical solutions of the present application and not to limit it. Although the present application has been described in detail through the above preferred embodiments, those skilled in the art should understand that various changes can be made in form and details without departing from the scope defined by the claims of the present application.
Claims
1. A method for producing amorphous zirconia having a chemohydraulic therapeutic effect, characterized by: Comprising the following steps: (1) Dissolve zirconium oxychloride octahydrate in deionized water and stir for 5 min. Add a certain volume ratio of ammonia water and stir for 5 min; (2) Transfer the solution of the above step to a high-pressure reaction kettle for hydrothermal reaction, react at 150 ℃ for 3 h, after the reaction is completed, when the temperature of the reaction kettle drops to room temperature, centrifuge the obtained material, wash it with deionized water for three times respectively, and finally place it in a 60 ℃ drying oven for 12 h to obtain the final material.
2. The method of claim 1, wherein the amorphous zirconium oxide having a chemodynamic therapeutic effect is prepared by the method comprising: The concentration of zirconium oxychloride octahydrate in step (1) is 0.1-0.5 mg / mL. 3. The method for preparing amorphous zirconia with chemodynamic therapeutic effects according to claim 1, characterized in that: The concentration of ammonia water in step (1) is 20%-30%.
4. The method for preparing amorphous zirconia with chemodynamic therapeutic effects according to claim 1, characterized in that: The volume ratio of zirconium oxychloride octahydrate to ammonia water in step (1) is 2:1.